Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (also referenced as Quoin Pharmaceuticals, Ltd. in metadata) on May 17, 2017. The filing reports on a material corporate event regarding a shareholder arrangement approved during an extraordinary meeting held on May 9, 2017.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance and legal proceedings rather than financial performance.
Material Changes
- Shareholder Approval: On May 9, 2017, shareholders, ADS holders, and Series-1 Stock Option holders approved an "Arrangement" previously proposed in a Form 6-K filed on April 4, 2017.
- Court Submission: On May 14, 2017, the Company submitted a request to the Central District Court in Lod for approval of the Arrangement.
- Objection Period: Stakeholders wishing to object to the Arrangement must submit objections to the Court by May 26, 2017.
Outlook, Risks, and Contingencies
The primary contingency is the pending approval of the Arrangement by the Central District Court in Lod. The filing notes that the report is incorporated by reference into the Company's Registration Statement on Form S-8 filed on November 28, 2016. No specific financial guidance or management commentary on future operations is provided in this text.
Key Facts for Investor Verification
- Verify the final ruling of the Central District Court in Lod regarding the Arrangement.
- Confirm whether any objections were filed by the May 26, 2017 deadline.
- Review the details of the "Arrangement" in the April 4, 2017 Form 6-K (Exhibit 99.1) to understand the specific terms approved by shareholders.
- Check subsequent filings for updates on the Form S-8 registration status.